From the Research
Definition and Explanation
- There is no information available on "Zeltivemikab" in the provided studies 1, 2, 3, 4, 5.
- The studies provided are related to "Ziprasidone", an atypical antipsychotic medication, and its use in the treatment of schizophrenia and schizoaffective disorder.
Related Information
- Ziprasidone is a benzisothiazolyl piperazine-type atypical antipsychotic that shares the serotonin(2A)/dopamine(2) (5-HT(2A)/D(2)) profile of the available atypical antipsychotics 2.
- It has demonstrated in vitro activity as a 5-HT(1A) receptor agonist and as a very weak inhibitor of serotonin and norepinephrine reuptake 2.
- Ziprasidone has been shown to be efficacious in the treatment of patients with acute exacerbations of schizophrenia or schizoaffective disorder 2, 3, 4, 5.
Studies and Findings
- The studies provided do not mention "Zeltivemikab" and are focused on the pharmacology, clinical efficacy, and adverse effects of Ziprasidone 1, 2, 3, 4, 5.
- The findings of these studies suggest that Ziprasidone is a safe and efficacious atypical antipsychotic for the acute management of schizophrenia, with a favorable tolerability profile 2, 3, 4, 5.